Octreotide Acetate NDC 23155-686

NDC codes

FDA NDC Directory

Product NDC (as listed)23155-686Labeler and product segments. Claims need a package NDC.

Product NDC at billing width23155-0686Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
23155-686-31	23155068631	5 mL in 1 VIAL, GLASS (23155-686-31)Marketed from May 25, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Octreotide Acetate
Generic name (nonproprietary): octreotide acetate
Active ingredients: Octreotide acetate — 1000 ug/mL
Dosage form: Injection, Solution
Route: Intravenous, Subcutaneous
Labeler: Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 203765
Marketing start: May 25, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Somatostatin Receptor Agonists (Mechanism)
Identifiers: Product ID 23155-686_b90ce9b0-5886-4b4f-a721-9698fa28a7ecSPL ID b90ce9b0-5886-4b4f-a721-9698fa28a7ecSPL set ID ffaf9462-cdd8-433b-8b03-464a35577fe9RxCUI 312068, 312069, 312070, 312071, 314152UNII 75R0U2568IUPC 0323155689310, 0323155687316, 0323155688313
Pharmacologic class: Somatostatin Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N423155068631 followed by a unit qualifier and the quantity

Package 23155-0686-31. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 3, 2024.

Indications (excerpt from the label)

Octreotide acetate injection is a somatostatin analogue indicated: • Acromegaly: To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) • Carcinoid Tumors: For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) • V asoactive Intestinal Peptide Tumors (VIPomas): For the treatment of profuse watery diarrhea associated with VIP-secreti…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 203765

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 203765
Product	Strength	Form · route	Labeler	Product NDC
Octreotide Acetate	Octreotide acetate 200 ug/mL	Injection, SolutionIntravenous, Intravenous	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-685